PDCD1 and neoplasm: In both Panc02 and MPC-83 tumor models, we found that anti-CD47 mAb or anti-PD-L1 mAb treatment alone or in combination increased the proportion of PD-1+CD8+ T lymphocytes in the peripheral blood, spleens, or tumors, when compared to that of untreated animals.